Congestive Heart Failure
Cardiovascular disease is the leading cause of death of men and women in the United States, and accounts for more than one-third (34.3%) of all U.S. deaths
Clinical studies have demonstrated that cardiovascular disease and damage to the vascular system starts years before it can be detected with current testing methods, (such as blood pressure, lipid panels, EKG or angiograms); this damage impairs vascular health and eventually makes its presence known later as high blood pressure and elevated cholesterol levels; after significant damage has already been done to the vascular system.
What is AngioDefender?
The AngioDefender by Everist Genomics is the world’s first non-invasive CVD testing system. With breakthrough technology combining non-invasive sensor technology with a sophisticated software algorithm, the AngioDefender is able to quickly and cost-effectively help physicians assess the presence of early stage CVD and atherosclerosis in asymptomatic patients. The most effective way to prevent more serious forms of CVD such as severe hypertension, atherosclerosis, congestive heart failure and stroke, is early diagnoses and treatment
|Jan 27 2012
Smartphone Technology Meets Personalized Medicine in Everist Genomics' CardioDefender Diagnostic System
|Dec 06 2011
Everist Genomics Discovers Genes Responsible for Recurrence of Colorectal Cancer
|Nov 09 2011
Everist Genomics to Launch CardioDefender: World's Only Mobile ECG System that Delivers Real-Time, Beat-by-Beat, Quantitative Heart Monitoring Data to Physicians
Results Reported Rapidly
The AngioDefender testing can be performed and results reported in about 15 minutes.LEARN MORE >>
AngioDefender testing is non-invasive and is applicable to any patient, regardless of age, gender, ethnicity or pre-existing conditions, and test results are not dependent on user technique or operator proficiency.LEARN MORE >>
AngioDefender smartphone, tablet, and mobile applications enable healthcare professionals to access patient diagnostic and therapeutic information throughout the day and from any location. This improves quality of care and reduces the cost of patient care.LEARN MORE >>
Frequently Asked Questions
Clinical validation of the AngioDefender device has been completed1 in 6 clinical evaluations around the world and has demonstrated a strong correlation to the current gold-standard, BAUI.
For more information on AngioDefender, pleaseContact Us